Press Release

Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with BeiGene for Fully Human Monoclonal Antibody Drug Discovery

January 08, 2018

Harbour BioMed
on WeChat

Back to list

Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with BeiGene for Fully Human Monoclonal Antibody Drug Discovery

January 08, 2018

January 7, 2018



Harbour BioMed announced today that it has licensed its patented H2L2 transgenic mouse platform for generating fully human therapeutic monoclonal antibodies, to BeiGene, Ltd. (NASDAQ: BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The license was issued through Harbour BioMed’s wholly owned subsidiary, Harbour Antibodies BV.


Harbour BioMed’s transgenic H2L2 platform enables biotechnology and pharmaceutical companies and academia to accelerate new drug development by generating fully human monoclonal antibodies. Under the licensing agreement, BeiGene has rights to use the H2L2 platform for multiple programs over a multi-year period.  Financial details were not disclosed.


“Over 30 companies and academic institutions globally have licensed our transgenic mouse platforms for their fully human monoclonal antibody discovery, with several programs at IND-ready stage, and one entered into clinical trial.” said Dr. Jingsong Wang, CEO of Harbour BioMed. “The increasing adoption of our platforms reflects their power as rapid and efficient antibody discovery tools and our strong intellectual property position.” Dr. Wang noted that the transgenic mouse platform licensing operations at Harbour Antibodies complements Harbour BioMed’s therapeutic discovery and development business.



About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. 


For further information, please refer to



About Harbour Mice


A fully owned subsidiary of Harbour BioMed, Harbour Antibodies owns two strains of transgenic mice for generating human therapeutic antibodies: (1) mice that generate antibodies comprised of two heavy chains and two light chains (H2L2) with fully human variable regions; and (2) mice that generate novel “heavy chain only” antibodies (HCAb). The HCAb mice enable the development of antibody fragment-based therapeutics such as nanobodies, bi-specific antibodies and CAR-T with favorable biophysical properties.


For more information, please visit





Timothy Miller

Harbour Antibodies

90 Bridge Street, Suite 100 

Newton, MA 02478, USA


Xian Wu

Harbour BioMed

866 Halei Road, Suite 311

Zhangjiang Hi-Tech Park, Shanghai, China 201203

Media Contact:

Harbour BioMed Public Relations